GET DAILY SIGNALSAN2 Therapeutics (ANTX): Analyst Target at $9 Signals +125% Upside Potential
Key Takeaways
- The central stock price target of $9.00 is the arithmetic mean of two current, verified analyst price targets, both set at $9.
- With the shares recently trading around $4, reaching $9 would require a rise of roughly 125%, a very large move.
- The current analyst range is unusually narrow at $9–$9, because only two firms — Guggenheim and Leerink Partners — carry active, current targets on the name.
- The strongest supporting factors are a reoriented clinical pipeline centered on epetraborole in polycythemia vera and refractory Mycobacterium abscessus lung disease, plus recent analyst upgrades and initiations.
- The biggest risks are that ANTX is a pre-revenue, clinical-stage biopharmaceutical company with a limited cash runway and binary trial outcomes.
- Historical targets from 2024–2025 were far lower (as low as $2), underscoring how sharply analyst expectations have shifted.
- Readers can find additional detail on the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- For broader market context, explore Trending AI Robots to see how automated strategies are reading current conditions.
Analyst Price Targets and Consensus View
AN2 Therapeutics, Inc. (NASDAQ: ANTX) is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on small-molecule therapeutics derived from its boron-chemistry platform. Its lead programs target polycythemia vera, non-tuberculous mycobacterial lung disease, Chagas disease, and melioidosis.
Only two current, attributable analyst price targets were identified, and both sit at $9. Guggenheim analyst Brad Canino initiated coverage with a Buy rating and a $9 target on July 20, 2026, while Leerink Partners analyst Joseph Schwartz upgraded the stock to Outperform from Market Perform with a $9 target on May 14, 2026. The arithmetic mean of these two valid targets is therefore $9.00, which is the central target used throughout this article. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
This is a thin consensus: with just two firms carrying active targets, the "average analyst price target" rests on a narrow base, and the $9–$9 range overstates agreement. For context, earlier coverage was markedly more cautious — Evercore ISI and JMP Securities previously held targets around $2 in 2024–2025. The jump from $2 to $9 reflects a meaningful reassessment of the company's reprioritized pipeline rather than broad sell-side consensus. A $9 target should be read as an optimistic, catalysts-driven view, not a guarantee.
Current Market Position and Path Toward the Target
The shares have been volatile, with a 52-week range of $1.00 to $7.19. After trading near $4 in recent sessions, ANTX would need to climb roughly 125% to reach $9 — a very large move that would require not just execution but also a sustained re-rating of the stock.
The path toward such a level is fundamentally event-driven. As a pre-revenue company, AN2 Therapeutics relies on clinical data readouts, regulatory milestones, and financing decisions to move its shares. The company reported first-quarter 2026 results and has reiterated its focus on epetraborole across polycythemia vera and refractory M. abscessus lung disease. Any target near $9 implicitly assumes positive trial data and a viable path to registration in at least one indication, which is far from assured.
What Could Support a Move Toward the Target
- Pipeline reprioritization: Focusing epetraborole on polycythemia vera and refractory M. abscessus lung disease targets areas with limited approved options, potentially supporting a premium valuation on success.
- Analyst momentum: A fresh Buy initiation from Guggenheim and an upgrade from Leerink Partners both carrying $9 targets signal renewed institutional interest.
- Non-dilutive funding: The company's global-health programs in melioidosis and tuberculosis are partly funded through grants, which can extend the cash runway.
- Low valuation base: A market capitalization of roughly $150–170 million leaves substantial room for appreciation if clinical milestones are met.
What Could Prevent the Target From Being Reached
- Binary clinical risk: A failed or underwhelming trial readout in a lead indication could sharply reset the stock, as past data disappointments have shown.
- Cash runway and dilution: As a clinical-stage company with negative EPS (earnings per share) of about -$1.05 on a trailing basis, AN2 may need to raise capital, which can dilute existing holders.
- Thin coverage and wide historical range: The gap between the current $9 targets and the earlier $2 targets illustrates how quickly sentiment can swing on a single data point.
- Competition: Larger biopharma companies are active in polycythemia vera and infectious disease, and any new competitive data could weigh on the outlook.
Technical Levels and Market Structure
The stock's 52-week range of $1.00 to $7.19 frames the relevant structure. The $7 area, near the recent high, is a natural resistance level that would need to be cleared before a move toward $9 becomes plausible. On the downside, the $3.50–$4.00 zone has served as an area of consolidation, while the $1 level marks a psychological and historical support level. A decisive break above $7.19, sustained on volume, would be an important technical confirmation of the bullish narrative; failure to hold above $4 could signal renewed selling pressure.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though no explicit horizon was stated in the two current reports, and the two targets carry the same figure despite differing initiation and upgrade dates. Investors should watch the next quarterly earnings release and cash-position commentary, upcoming trial data and regulatory updates for epetraborole, any financing or partnership announcements, and further analyst revisions. Changes to the target from either Guggenheim or Leerink Partners — or the addition of new coverage — would materially reshape the average. From what I see, monitoring these catalysts closely makes sense for anyone following the name.
Monitoring with AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like AN2 Therapeutics, this kind of automated monitoring can help traders spot shifting trends and manage positions more efficiently without watching every tick. Traders can use the signals to discover new opportunities, monitor existing holdings, and react more quickly to changes in momentum. I find it useful for staying on top of momentum shifts in names like this without constant screen time. Explore AI Daily Buy/Sell Signals to see how the platform reads current market conditions.
Final Assessment
Can ANTX reach $9? The target is real but rests on a narrow base — two current analyst reports, both at $9, implying a roughly 125% advance from recent prices around $4. The bullish case depends on successful clinical execution and a re-rating of a pipeline now centered on epetraborole in polycythemia vera and refractory M. abscessus lung disease. The bearish case points to binary trial risk, a limited cash runway, and the fact that sell-side views on this stock have swung from $2 to $9 in the space of about a year. The $9 figure represents an optimistic, catalyst-dependent objective rather than a consensus anchored by broad coverage. What happens next will be driven by data readouts, financing decisions, and any analyst revisions — not by the target itself.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ANTX in +21.50% Uptrend, growing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ANTX advanced for three days, in 199 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANTX's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ANTX as a result. In 62 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ANTX just turned positive on October 27, 2026. Looking at past instances where ANTX's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where ANTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
ANTX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
ANTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ANTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.988) is normal, around the industry mean (3.498). P/E Ratio (-3.810) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement